{"disease":{"id":"maintenance-treatment-of-copd","name":"maintenance treatment of copd"},"drugs":{"marketed":[{"drug_id":"aclidinium-bromide","indication_name":"Maintenance treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tudorza Pressair","generic_name":"ACLIDINIUM BROMIDE","company_name":"Covis","drug_phase":"marketed","molecular_target":"M3 receptors, beta 2 -adrenergic receptors","drug_class":"Anticholinergic","quality_score":54,"revenue":null,"mechanism":"DUAKLIR PRESSAIR combines aclidinium, an anticholinergic, and formoterol, a beta 2 -adrenergic agonist, to provide bronchodilation in COPD."},{"drug_id":"salmeterol-xinafoate","indication_name":"Maintenance Treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SALMETEROL XINAFOATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"budesonide-and-formoterol","indication_name":"Maintenance Treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"budesonide and formoterol","company_name":"National Jewish Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor, beta 2 -adrenoceptor","drug_class":"Corticosteroid [EPC]","quality_score":60,"revenue":null,"mechanism":"Budesonide reduces inflammation, while formoterol relaxes airway muscles, together improving symptoms of COPD and asthma."},{"drug_id":"tiotropium","indication_name":"Maintenance treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TIOTROPIUM","company_name":"","drug_phase":"marketed","molecular_target":"M3 receptors, beta2-adrenoceptors","drug_class":"","quality_score":48,"revenue":null,"mechanism":"STIOLTO RESPIMAT combines tiotropium, an anticholinergic, and olodaterol, a beta-agonist, to achieve bronchodilation through different mechanisms."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}